Pharmexa receives U.S. patent for GV1001 vaccine for pancreatic cancer

By Lisa Kerner

Erie, Pa., April 24 - Pharmexa AS said it has been granted a U.S. patent for GV1001, its peptide vaccine targeting telomerase currently under preparation for phase 3 trials in pancreatic cancer.

The patent claims cover specific peptides, including the GV1001 vaccine, and their use in cancer immunotherapy, according to a company news release.

The vaccine is also patented in Europe and Australia.

Located in Horsholm, Denmark, Pharmexa develops immunotherapy and vaccines for the treatment of chronic and infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.